Of note, not all cases in this study were found to have genetic alterations in EZH2 or other PRC2 core factors, suggesting that reduced PRC2 function might be a convergent molecular mechanism for AML treatment resistance. The gene discussed is EZH2; the disease is acute myeloid leukemia.